Clinical Trial Results: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab plus lenvatinib plus chemotherapy in metastatic esophageal squamous cell carcinoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Chemotherapy (chemotherapy)
• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2026-07-20